A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

JNJ-70218902, the investigational drug, has been shown in pre-clinical studies to work by attaching to cancer cells and activating immune cells to kill these cancer cells. This study will be conducted in 2 parts: dose escalation (Part 1) and dose expansion (Part 2) and will enroll adult men with Metastatic Castration-Resistant Prostate Cancer (MCRPC). Study evaluations will include preliminary clinical efficacy, safety, pharmacokinetics, biomarkers and immunogenicity evaluations. This study is divided into 3 periods: screening, treatment and post-treatment. The total duration of the study will be 2.5 years approximately.

Inclusion Criteria:

• Histology: Metastatic castration-resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine features is allowed
• Measurable or evaluable disease
• Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
• If the participant is receiving treatment with gonadotropin-releasing hormone agonists or antagonist analogs (GnRH), this therapy must have been initiated prior to first dose of study drug and must be continued throughout the study
• Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
• Adequate organs functions

Exclusion Criteria:

• Known brain metastases
• Concurrent use of any other anticancer treatment or investigational agent for the treatment of advanced disease
• Toxicities related to prior anticancer treatments have not returned to Grade less than or equal to (<=) 1 or baseline, except for alopecia and vitiligo
• Solid organ or bone marrow transplantation
• Known allergies, hypersensitivity, or intolerance to JNJ-70218902 or its excipients
• Certain comorbidities